iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.14974 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Rosemarie Lajara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Southern Endocrinology, Plano, Texas, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare outcomes in adults with type 2 diabetes (T2D) suboptimally controlled with basal insulin who initiated treatment with iGlarLixi or premixed insulin.
Methods
This retrospective real‐world analysis was conducted using data from adults (age ≥ 18 years) with T2D in the US Optum Clinformatics database who had previously received basal insulin and newly initiated iGlarLixi or premixed insulin. Cohorts were propensity‐score matched on baseline characteristics using a greedy nearest neighbour‐matching algorithm, and outcomes were assessed at 12 months. Subgroup analyses were performed for those aged 65 years or older and those with a baseline HbA1c of 9% or higher. The primary endpoint was treatment persistence in the overall population. Secondary endpoints were treatment adherence, healthcare resource utilization (HRU), costs, hypoglycaemia events and change in HbA1c from baseline.
Results
Each cohort comprised 834 participants. In the overall population, treatment persistence at 12 months was statistically significantly higher for iGlarLixi versus premixed insulin: 42.5% versus 39.1%; hazard ratio 0.88; 95% confidence interval 0.778‐0.998; P = .0465. Adherence and HbA1c reduction were similar between groups, whereas hypoglycaemia events, HRU and costs were numerically lower for iGlarLixi. Outcomes in both the age 65 years or older subgroup and in those with an HbA1c of 9% or higher were consistent with those for the overall population.
Conclusions
In this observational study in people with T2D suboptimally controlled on basal insulin, once‐daily iGlarLixi was an effective treatment alternative to premixed insulin with significantly higher treatment persistence, similar adherence and HbA1c reduction, and numerically lower hypoglycaemia events, HRU and costs, regardless of age or baseline HbA1c.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Southern Endocrinology, Plano, Texas, USA.
- Aetion, New York, New York, USA.
- Cleveland Clinic, Cleveland, Ohio, USA.
- Sanofi, Paris, France.
- Sanofi, Bridgewater, New Jersey, USA.
- Washington Regional Endocrinology, Fayetteville, Arkansas, USA.
ORCID-Profile: Rosemarie Lajara, Kevin M Pantalone, Elisheva Lew
Förderung
- Sanofi
Zitieren
APA
Lajara, R., Heller, C., Pantalone, K. M., Lew, E., Li, X., Dex, T., & Kilpatrick, C. R. (2023). iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14974
Vancouver
Lajara R, Heller C, Pantalone KM, Lew E, Li X, Dex T, et al. iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.14974
BibTeX
@article{Lajara2023,
author = {Lajara, Rosemarie and Heller, Caroline and Pantalone, Kevin M and Lew, Elisheva and Li, Xuan and Dex, Terry and Kilpatrick, Catherine Rachel},
title = {iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.14974}
}
EUVIMED